Commentary on “Pasireotide for postoperative pancreatic fistula”
Commentary on Smarter drugs emerging in pancreatic cancer therapy by A. Kleger, L. Perkhofer & T. Seufferlein, Ulm University, Ulm, Germany.
Extended pancreatectomy in pancreatic ductal adenocarcinoma: Definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS).
Commentary on “Pancreatectomy for metastatic disease: A systematic review”- Adler et al, European Journal of Surgical Oncology 2014;40(4): 379-86.
Commentary on Adjuvant chemotherapy in elderly patients with pancreatic cancer by Nagrial et al, BJC 2014, 110:313-219.
Pancreatic cancer update from ESMO World Congress on GI Cancers 25-28th June/ 2014
Commentary on Management of locally advanced pancreatic cancer (LAPC) -European society of digestive oncology (ESDO) expert discussion and recommendation from the 14th ESMO world congress on GI cancer ( Seufferlein et al; annals of Oncol; 2014;25(Suppl 2)ii1-ii4.
Pancreatic resection for locally advanced pancreatic cancer
Commentary on Locally Advanced Pancreatic Cancer – ‘Primum non nocere’.Savio G. Barreto, Consultant Surgeon, Gastrointestinal Surgery, Gastrointestinal Oncology, and Bariatric Surgery, Institute of Digestive and Hepatobiliary Sciences, Medanta, The Medicity, Gurgaon – India
Commentary on the consensus statement on borderline resectable pancreatic cancer by ISGPS. Surgery 2014;155:977-88
Commentary on SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study by Sinn et al. Annals Oncology 2014; 25: 1025–1032:
Towards Imparting Personalized Therapy to Pancreatic Cancer patients
Pancreatic cancer update from GI ASCO 2014
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer
Adjuvant gemcitabine for pancreatic cancer
Potential practice changing Update on Pancreatic cancer from ASCO 2013
Commentary for pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreatico-duodenectomy for pancreatic or periampullary tumours: a multicentre randomized trial
Immunohistochemically Detected Expression of 3 Major Genes (CDKN2A/p16, TP53, and SMAD4/DPC4) Strongly Predicts Survival in Patients With Resectable Pancreatic Cancer
Commentary on Induction Gemcitabine and Oxaliplatin Therapy Followed by a Twice-Weekly Infusion of Gemcitabine and Concurrent external-Beam Radiation for Neoadjuvant Treatment of Locally Advanced Pancreatic Cancer (Leone et al, Cancer; 2013 Jan 15;119(2):277-84)
Randomized, placebo-controlled, double-blind, parallel-group phase III study evaluating Aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. By Chang DK et al . JCO 2013,31;1-9
Commentary on SCALOP trial: a multicentre, randomised, phase 2 trial. The Lancet Oncology. 2013 Apr;14(4):317-26.
Malignant Progression in IPMN: A Cohort Analysis of Patients Initially Selected for Resection or Observation. J. LaFemina et al. Ann Surg Oncol 2012
Pancreatic Cancers and the Role of EGFR Pathway
Radiotherapy Technical Considerations in the Management of Locally Advanced Pancreatic Cancer:American-French Consensus Recommendations (IJROBP 2011)
Expert commentary on “New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel” Ann Oncology 2012; 23: 570-6.
Incidental Nonfunctional Pancreatic Endocrine Tumors (NPET) -
Tumor behavior, Clinical management and Outcome.
Adjuvant S1 significantly prolongs overall survival over standard of care Gemcitabine: ASCO GI Abstract 145
Abraxane combination improves outcome in advanced pancreatic cancer